Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine.

被引：0
|
作者：
Keating, MJ
Byrd, J
Rai, K
Flinn, I
Jain, V
Binet, JL
Bolin, R
Hillmen, P
Hutchinson, M
机构：
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3118
引用
收藏
页码：705A / 705A
页数：1
相关论文
共 50 条
  • [31] Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
    Bowen, AL
    Zomas, A
    Emmett, E
    Matutes, E
    Dyer, MJS
    Catovsky, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (03) : 617 - 619
  • [32] Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
    Anders Osterborg
    Hakan Mellstedt
    Michael Keating
    Medical Oncology, 2002, 19 : S21 - S26
  • [33] The monoclonal antibodies Campath-1H and rituximab in the therapy of chronic lymphocytic leukemia
    Schulz, H
    Winkler, U
    Staak, JO
    Engert, A
    ONKOLOGIE, 2000, 23 (06): : 526 - 532
  • [34] Fludarabine, Ara-c, novantrone and dexamethasone plus Campath-1H for the treatment of patients with chronic lymphocytic leukemia (CLL) and adverse clinical and biologic prognostic features.
    Mauro, Francesca R.
    Giammartini, Elena
    De Propris, Maria S.
    Gentile, Giuseppe
    Nanni, Mauro
    Ghia, Emanuela M.
    Della Starza, Irene
    Del Giudice, Ilaria
    Santangelo, Simona
    Marinelli, Marilisa
    Brugnoletti, Fulvia
    Minotti, Clara
    Capria, Vera
    Guarini, Anna
    Foa, Robert
    BLOOD, 2006, 108 (11) : 801A - 801A
  • [35] In vitro and in vivo cytotoxicity of fludarabine in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL)
    Hilgenfeld, E
    Knauf, WU
    Thiel, E
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 245 - 253
  • [36] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [37] In-vitro treatment of chronic lymphocytic leukemia (CLL) cells with fludarabine, etoposide and alemtuzumab (campath-1H) reveals different rates and mechanisms of cell death.
    Winkler, D
    Schneider, C
    Nitsch, D
    Habermann, A
    Doehner, H
    Stilgenbauer, S
    BLOOD, 2005, 106 (11) : 597A - 597A
  • [38] In vitro sensitivity of B-CLL cells to fludarabine, anti-CD20 (rituximab) and anti-CD52 (Campath-1H).
    Grdisa, M
    Ajchenbaum-Cymbalista, F
    Tang, RP
    Marie, JP
    Delmer, A
    BLOOD, 2000, 96 (11) : 161A - 161A
  • [39] CYCLOSPORINE-A IN THE TREATMENT OF REFRACTORY B-CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL)
    VANDENNESTE, E
    MAEREVOET, M
    MARTIAT, P
    FERRANT, A
    DELANNOY, A
    MICHAUX, JL
    LEUKEMIA, 1995, 9 (06) : 1102 - 1103
  • [40] Purging "in vivo" with alemtuzumab (Campath-1H) before autologous stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL)
    Montillo, M
    Tedeschi, A
    Cairoli, R
    Miqueleiz, S
    Scarpati, B
    Cafro, AM
    Intropido, L
    Farioli, R
    Veronese, S
    Morra, E
    BLOOD, 2005, 106 (11) : 821A - 822A
12345